Is there a non-surgical option for a worn thumb base?

For many people, the frustration of thumb basal joint pain is not the diagnosis — it is what comes after. Corticosteroid injections ease inflammation for weeks or months; hyaluronic acid and bracing manage symptoms with limited evidence of lasting structural benefit; and the surgical alternative, trapeziectomy, removes the trapezium bone permanently. Between those poles, there has historically been little to offer patients who want to address the cartilage loss itself without committing to an irreversible operation.

Thumb carpometacarpal (CMC) osteoarthritis is the second most common degenerative hand condition, affecting approximately 30% of postmenopausal women and causing progressive pain, pinch weakness, and loss of grip. The joint sits at the base of the thumb and is exposed to high contact forces with everyday tasks — making effective, durable treatment a practical priority rather than a quality-of-life luxury.

ChondroFiller injection is an ultrasound-guided outpatient procedure that delivers an injectable collagen scaffold directly into the CMC joint space. Rather than masking symptoms or removing bone, it targets the cartilage surface — working with the body's own progenitor cells to address the structural problem at its source. For suitable patients, this represents a credible middle path between conservative management and surgery.

How the collagen scaffold works once injected

The product itself contains no donor cells — ChondroFiller is an acellular type I collagen hydrogel, CE-marked as a Class III medical device by Meidrix Biomedicals in Germany. Class III is the highest regulatory tier for medical devices in Europe, applying to products that contact body tissue and carry a substantive performance claim; the classification reflects both the material's biological function and the regulatory scrutiny it has passed before reaching UK clinical use.

Administered as a liquid under ultrasound guidance, it reaches body temperature inside the joint space and sets within 3 to 15 minutes, forming a firm, porous scaffold that fills and cushions the cartilage defect. Its role is more than mechanical padding. The scaffold acts as a biological framework into which the body's own progenitor cells begin to migrate — a process called matrix-induced chondrogenesis. An ex vivo osteochondral study found a 2.4-fold increase in DNA content within the scaffold by day 14, confirming active cell recruitment at a cellular level; this is mechanistic evidence of the process rather than proof of complete cartilage regeneration in every case.

No bone drilling, incision, or general anaesthetic is required at any point. The biological repair response is driven entirely by the patient's own progenitor cells engaging with the scaffold — distinguishing this ultrasound-guided outpatient injection pathway, which is the current clinical service, from earlier or external research contexts in which ChondroFiller was delivered arthroscopically rather than by injection.

Which patients are most likely to benefit

Eaton-Littler staging gives clinician and patient a shared language for where the joint sits on the spectrum of wear. Grade I–II describes early-to-moderate damage: joint space partly preserved, cartilage loss focal, and the saddle-joint architecture largely intact. Grade III–IV indicates more substantial wear with narrowing, subchondral changes, and sometimes subluxation.

The strongest case for ChondroFiller injection sits at grade I–II, where grip strength recovery — in the 2025 Corain study of 64 patients — was most pronounced. Grade III–IV patients are not excluded: that same study found this group showed greater improvement in disability scores (DASH) sustained beyond two years of follow-up, even if grip strength gains were smaller. End-stage bone-on-bone disease lies outside the scope of this injection pathway, where a surgical discussion becomes the appropriate next step.

There is no published upper age limit, and the injectable volume can address defects up to approximately 3 cm², extendable to 6 cm² — so neither age nor defect size is an automatic barrier to assessment.

One practical caveat applies to all candidates. A biomechanical study found that ChondroFiller initially lacks full mechanical stability under cyclic loading, and post-procedure hand-use restriction is therefore part of the protocol. Patients who cannot reduce grip-heavy activity in the weeks following treatment — manual workers in particular — should factor this into the timing of the procedure.

What the clinical evidence shows

The centrepiece of the published evidence is a 2025 prospective study by Corain and colleagues (PMC12213533), which followed 64 patients with trapeziometacarpal osteoarthritis who received a percutaneous, ultrasound-guided ChondroFiller injection. All three primary outcome domains — pain on a numerical rating scale (NRS), grip and pinch strength measured by Jamar dynamometry, and functional disability by the DASH questionnaire — reached P<0.001, with improvements maintained at a follow-up of more than two years. That duration represents the longest published follow-up for this specific indication, and no adverse events were recorded across the cohort.

The grade-stratified response described earlier is, on the evidence, a feature rather than a caveat: it mirrors a dose–response relationship between disease stage and the type of functional gain most accessible at each stage. Most measurable improvement accrued between two and six months post-injection, which gives a practical reference window for gauging response.

Broader outcome figures from the London Cartilage Clinic cite 70–85% symptom relief across joints, with a reoperation rate of 3–8% — compared with published rates of 41% for microfracture and 37% for ACI. These comparisons carry the caveat that they aggregate across different joint sites and study designs, so they are better read as contextual benchmarks than as direct head-to-head data. A 2025 prospective wrist study (PMC12498443) adds supporting safety evidence, finding significantly better cartilage-quality scores versus controls (Outerbridge 1.5 vs 3.0, P=0.006) in a comparably sized small joint — useful corroboration of the material's behaviour, though not a substitute for thumb CMC–specific trial data.

The principal evidential gap is the absence of a large-scale randomised controlled trial targeting the thumb CMC joint. The Corain cohort of 64 patients is, to date, the most direct published evidence for this indication; it is clinically informative, but it does not yet meet the threshold that would typically support national guideline adoption. That limitation does not negate the findings, but it remains relevant to any discussion of where this treatment sits in the broader evidence hierarchy.

What the appointment and recovery involve

On the day itself, the appointment runs to roughly 30–45 minutes: arrival, preparation, injection, and a brief settling period before leaving. There is no inpatient admission, no wound to dress, and no post-operative monitoring period — patients walk in and walk out.

The part of recovery that requires planning is not pain or wound healing but hand loading. Because the scaffold needs time to integrate before it can withstand the cyclic forces of gripping and pinching, heavy hand use should be reduced in the weeks immediately following the injection. For desk-based workers and those with light daily hand demands, this restriction is typically manageable within a few weeks; for manual trades, patients who use grip-heavy tools, or those returning to racket sports or climbing, the restriction period is meaningfully longer and should be discussed at assessment so that timing can be planned around work or sport commitments. This is a designed feature of the protocol — not a complication — but it is the one logistical constraint that genuinely distinguishes the recovery from a simple anti-inflammatory injection.

How it fits alongside other treatment choices

For mild thumb CMC symptoms, conservative measures — bracing, physiotherapy, and guided corticosteroid or hyaluronic acid injection — remain the appropriate first step. None addresses underlying cartilage loss structurally, and long-term efficacy is debated, but they are low-risk and reversible.

When symptoms persist and staging confirms early-to-moderate disease with residual joint space, the ChondroFiller injection offers a non-surgical route that targets the cartilage defect rather than inflammation alone. A 2025 study of arthroscopic autologous fat plus PRP in 48 patients (Eaton II–IV) — activity pain reduced from 8.9 to 3.3 — illustrates a parallel shift toward joint-preservation approaches at this stage, though that route involves arthroscopy and sits in a different procedural category from an outpatient injection.

For advanced-stage disease where joint architecture is substantially compromised, trapeziectomy remains the most commonly performed surgical option in the UK. It is effective and the appropriate choice when preservation is no longer realistic; it is also irreversible, which makes the preceding decision window the clinically important one.

Access and cost

ChondroFiller is CE-marked in approximately 25 European countries and is not FDA-approved — relevant for patients enquiring from the United States or considering UK care from abroad. In the UK, the self-funded private cost runs from approximately £3,000 to £8,000 depending on volume; there is currently no NHS pathway.

The working decision logic runs: early-to-moderate staging, inadequate response to conservative care, and the ability to protect the hand during the scaffold integration period are the three conditions that make a ChondroFiller injection worth serious consideration. End-stage disease shifts the conversation toward surgical reconstruction. A consultation at the London Cartilage Clinic can help determine which pathway applies — bookings can be arranged via londoncartilage.com.

1. [1] Preservation Arthroplasty for Basal Joint Arthritis Using Arthroscopy and Autologous Fat Grafting With PRP. (2025). https://doi.org/10.1097/GOX.0000000000006720 https://doi.org/10.1097/GOX.0000000000006720
2. [2] The Effect of Ultrasound-Guided Steroid Injection on Progression to Surgery in Thumb CMC Arthritis. (2014). https://doi.org/10.1142/S0218810414500099 https://doi.org/10.1142/S0218810414500099
3. [3] Ex Vivo Osteochondral Biomimetic Platform for Cartilage Regeneration Mechanistic Investigation. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759